Promising early trial: patisiran may ease nerve damage in rare amyloidosis
NCT ID NCT05023889
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 20 times
Summary
This early-phase study looked at how well the drug patisiran works for people with a rare disease called wild-type ATTR amyloidosis that causes nerve damage. Ten adults received the treatment, and researchers tracked changes in nerve function, symptoms like dizziness and digestion issues, and overall quality of life over two years. The goal was to see if patisiran could help control the disease and improve daily living.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Neuromuscler Center/National Neuromuscular Research Institute
Austin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.